文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

PRKCQ-AS1/miR-582-3p表达在肺腺癌中的临床意义及生物学功能

Clinical significance and biological function of PRKCQ-AS1/miR-582-3p expression in LUAD.

作者信息

Liu Lingling, Liu Xiaofen, Wu Xiaojiao, Fang Hang, Shi Jingjing, Jiang Wei

机构信息

Integrated Chinese and Western Medicine Oncology, the First Hospital of Qiqihar, Qiqihar, 161000, China.

Department of Respiratory and Critical Care Medicine, Taikang Tongji (Wuhan) Hospital, Wuhan, 430050, China.

出版信息

Hereditas. 2025 Jul 1;162(1):116. doi: 10.1186/s41065-025-00482-9.

DOI:10.1186/s41065-025-00482-9
PMID:40597380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12211715/
Abstract

OBJECTIVE: To investigate the clinical value and mechanism of action of long non-coding RNA PRKCQ-AS1 for lung adenocarcinoma (LUAD) progression. METHODS: Clinical data of 128 LUAD patients were collected, postoperative pathological tissues were stored at -80 °C. Kaplan-Meier survival analysis was employed to investigate differences in 5-year survival rates across various expression groups, while Cox regression models assessed the prognostic factors influencing patient outcomes. Reverse transcription quantitative PCR (RT-qPCR) was utilized to measure the expression levels of PRKCQ-AS1 and miR-582-3p in pathological tissues and LUAD cell lines. Additionally, a dual-luciferase reporter assay validated the reciprocal relationship. CCK8 examined cell proliferation, Transwell observed cell migration and invasion. RESULTS: PRKCQ-AS1 was down-regulated and miR-582-3p was up-regulated in LUAD tissues and cell. PRKCQ-AS1 and miR-582-3p expression affects some pathological features (lymph node metastasis, TNM stage, tumour differentiation) in LUAD patients. Patients with low PRKCQ-AS1 and high miR-582-3p had increased mortality. Interaction of PRKCQ-AS1 targeting miR-582-3p exists in LUAD cells. RGMB, STXBP6 are downstream target genes of miR-582-3p. Overexpression of (oe-) PRKCQ-AS1 inhibited LUAD cell proliferation, migration, and invasion. However, concomitant use of miR-582-3p mimics resisted the effects of PRKCQ-AS1 overexpression on cells. CONCLUSION: PRKCQ-AS1/miR-582-3p axis regulatory relationship exists in lung adenocarcinoma cells. PRKCQ-AS1 may regulate the proliferation, migration and invasion of lung adenocarcinoma cells and participate in LUAD regulation by targeting miR-582-3p. CLINICAL TRIAL NUMBER: Not applicable.

摘要

目的：探讨长链非编码RNA PRKCQ-AS1在肺腺癌（LUAD）进展中的临床价值及作用机制。 方法：收集128例LUAD患者的临床资料，术后病理组织保存于-80°C。采用Kaplan-Meier生存分析研究不同表达组5年生存率的差异，同时用Cox回归模型评估影响患者预后的因素。利用逆转录定量PCR（RT-qPCR）检测病理组织和LUAD细胞系中PRKCQ-AS1和miR-582-3p的表达水平。此外，双荧光素酶报告基因检测验证了二者的相互关系。CCK8检测细胞增殖，Transwell观察细胞迁移和侵袭。 结果：PRKCQ-AS1在LUAD组织和细胞中表达下调，miR-582-3p表达上调。PRKCQ-AS1和miR-582-3p的表达影响LUAD患者的一些病理特征（淋巴结转移、TNM分期、肿瘤分化）。PRKCQ-AS1低表达和miR-582-3p高表达的患者死亡率增加。在LUAD细胞中存在PRKCQ-AS1靶向miR-582-3p的相互作用。RGMB、STXBP6是miR-582-3p的下游靶基因。过表达（oe-）PRKCQ-AS1可抑制LUAD细胞的增殖、迁移和侵袭。然而，同时使用miR-582-3p模拟物可抵抗PRKCQ-AS1过表达对细胞的影响。 结论：肺腺癌细胞中存在PRKCQ-AS1/miR-582-3p轴调控关系。PRKCQ-AS1可能通过靶向miR-582-3p调控肺腺癌细胞的增殖、迁移和侵袭，并参与LUAD的调控。 临床试验编号：不适用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/74e2625be838/41065_2025_482_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/d7affc50d3a5/41065_2025_482_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/ea7fad452593/41065_2025_482_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/d41838c63b95/41065_2025_482_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/8ef4ea598e02/41065_2025_482_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/74e2625be838/41065_2025_482_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/d7affc50d3a5/41065_2025_482_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/ea7fad452593/41065_2025_482_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/d41838c63b95/41065_2025_482_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/8ef4ea598e02/41065_2025_482_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3552/12211715/74e2625be838/41065_2025_482_Fig5_HTML.jpg

相似文献

[1]
Clinical significance and biological function of PRKCQ-AS1/miR-582-3p expression in LUAD.

Hereditas. 2025-7-1

[2]
Caveolin-1 inhibits the proliferation and invasion of lung adenocarcinoma via EGFR degradation.

Sci Rep. 2025-7-1

[3]
Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression.

Bioengineered. 2022-3

[4]
ADRB2 is regulated by TRIM22 and facilitates lung adenocarcinoma progression via JAK2/STAT3 signaling pathway.

Sci Rep. 2025-7-1

[5]
The long noncoding RNA LINC00483 promotes lung adenocarcinoma progression by sponging miR-204-3p.

Cell Mol Biol Lett. 2019-12-16

[6]
LncRNA FAM66C predicts poor prognosis in patients with lung adenocarcinoma and regulates cell proliferation and metastasis via miR-339-3p.

J Cardiothorac Surg. 2025-4-2

[7]
Long non-coding RNA GATA6-AS1 upregulates GATA6 to regulate the biological behaviors of lung adenocarcinoma cells.

BMC Pulm Med. 2021-5-15

[8]
Long noncoding RNA FBXL19-AS1 induces tumor growth and metastasis by sponging miR-203a-3p in lung adenocarcinoma.

J Cell Physiol. 2020-4

[9]
Unraveling the role of GPCR signaling in metabolic reprogramming and immune microenvironment of lung adenocarcinoma: a multi-omics study with experimental validation.

Front Immunol. 2025-6-6

[10]
LncRNA OIP5-AS1 suppresses lung adenocarcinoma progression and modulates macrophage polarization through the miR-429/DOCK4 regulatory axis.

Front Pharmacol. 2025-5-20

本文引用的文献

[1]
Circular RNA ATP9A Stimulates Non-small Cell Lung Cancer Progression via MicroRNA-582-3p/Ribosomal Protein Large P0 Axis and Activating Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway.

Appl Biochem Biotechnol. 2025-5

[2]
Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt/β-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo.

Hereditas. 2024-11-27

[3]
Silencing PPAP2C inhibits lung adenocarcinoma migration and invasion via the ERK/JNK pathway.

Mol Med Rep. 2025-1

[4]
Emerging roles of long non-coding RNA FOXP4-AS1 in human cancers: From molecular biology to clinical application.

Heliyon. 2024-10-26

[5]
Integration analysis of - and -regulatory long non-coding RNAs associated with immune-related pathways in non-small cell lung cancer.

Biochem Biophys Rep. 2024-10-28

[6]
Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research.

Front Oncol. 2024-10-29

[7]
Hsa_circRNA_000166 accelerates breast cancer progression via the regulation of the miR-326/ELK1 and miR-330-5p/ELK1 axes.

Ann Med. 2024-12

[8]
METTL14 regulates inflammation in ulcerative colitis via the lncRNA DHRS4-AS1/miR-206/A3AR axis.

Cell Biol Toxicol. 2024-11-11

[9]
Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma.

Sci Rep. 2024-11-11

[10]
NLRP12/C1qA positive feedback in tumor-associated macrophages regulates immunosuppression through LILRB4/NF-κB pathway in lung adenocarcinoma.

Cancer Immunol Immunother. 2024-11-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索